Immatics Biotechnologies Gmbh

Morphosys Ag

Immatics Us, Inc.

Emmatics Biotechmiogieg Gmbh

Mann+hummel Gmbh

Mahle Behr Gmbh & Co. Kg

Claudia Wagner

Jens Fritsche

Toni Weinschenk

Andrea Mahr

Oliver Schoor

Harpreet Singh

Dominik Maurer

Sebastian Bunk

Leonie Alten

Martina Ott

Colette Song

Julia Leibold

Felix Unverdorben

Martin Hofmann

Meike Hutt

Mathias Ferber

Heiko Schuster

Franziska Hoffgaard

Franco Ghiani

Gisela Schimmack

Gunnar-Marcel Klein

Frank Schwoebel

Andreas Moritz

Alexandra Kraus

Thorsten Schmid

Peter Klein

Sara Yousef

Gabriele Pszolla

Ali Mohamed

Amir Alpert

Klaus Felix Hartlepp

Florian Schwoerer

Fabian Brunk

Anastasiya Smith

Harald Banzhaf

Maike Jaworski

Jens Kögel

Christof Well

Sandra Grausam

Otto Stilz

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

The present invention relates to modified T cell receptor (TCR) α or β chains, or heterodimers comprising the same, wherein in the variable domain of said modified α or β chain, an amino acid at position 44 according to the IMGT numbering is substituted by another suitable amino acid in order to improve pairing of desired chains.

T cell receptors with improved pairing

The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Antigen binding proteins specifically binding MAGE-A

The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain Vcomprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain Vcomprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.

Antigen binding proteins specifically binding CT45

The present invention relates to a method for high throughput screening for a TCR-binding peptide ligand/MHC molecule complex, comprising a stabilized peptide-MHC molecule and respective uses of said method. The present invention further relates to polypeptides comprising or consisting of stabilized MHC molecules or peptide binding fragments thereof, pharmaceutical compositions comprising said polypeptides, vaccines comprising said pharmaceutical composition and uses of said vaccine for the manufacturing of a medicament and/or in the prevention of cancer The present invention further relates to nucleic acids encoding said polypeptides and vectors comprising said nucleic acids.

Method for high throughput peptide-MHC affinity screening for TCR ligands

Described herein are methods for preparing T cells, including isolating CD8+ T cells from a blood sample obtained from a patient or a donor, culturing the isolated CD8+ T cells in the presence of at least one cytokine, contacting the cultured CD8+ T cells with a multimer containing a target peptide in a complex with an MHC molecule and with at least one binding agent that binds to a T cell surface molecule, in which the multimer is labelled with a first detectable agent and the binding agent is labelled with a second detectable agent, sorting the contacted CD8+ T cells to collect the sorted CD8+ T cells that are detected positive for the first and the second detectable agents, and expanding the collected CD8+ T cells.

Methods for manufacturing T cells by direct sorting and compositions thereof

The present invention pertains to antigen recognizing constructs against tumor associated antigens (MAGEA1). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

T cell receptors and immune therapy using the same

The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Engineered T cell receptors and immune therapy using the same

The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Antigen binding proteins specifically binding PRAME

Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC and other cancers

The present invention pertains to antigen recognizing constructs against tumor associated antigens (TAA), in particular against Preferentially Expressed Antigen of Melanoma (PRAME). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the tumor expressed antigen of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

T cell receptors and immune therapy using the same against PRAME positive cancers

Growing community of inventors

Tuebingen, Germany

Claudia Wagner